Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy Primocure

NCT04045561 | Completed

• 1 other identifier: LOCAL/2015/MF-01
• Study Type: observational
• Target: 10
• Locations: 0 countries
• Sites: N/A

Brief Summary

The hypothesis is that the implementation of an initial Pharmaceutical Consultation (PC) program based on the provision of standardized information to patients treated for multiple myeloma as a first course of chemotherapy, could optimize their compliance with the delivered per os treatment. The aim of this study is therefore to develop a standardised reference guide of information to be provided during prostate cancer in order to optimise the compliance of patients treated for multiple myeloma as a first course of chemotherapy per os.

Conditions

Multiple Myeloma

Outcome Measures

Primary Outcomes (4)

• evaluating the understanding

  Questionnaire. quantitative variables: measurement of the mean and standard deviation or by their median and quartiles according to their distribution.

  Day 1

• evaluating understanding

  Questionnaire. qualitative variables: measurement of their number and

  Day 1

• evaluating the quality of information

  Questionnaire. quantitative variables: measurement of the mean and standard deviation or by their median and quartiles according to their distribution.

  Day 1

• evaluating quality of information

  Questionnaire. qualitative variables: measurement of their number and percentage.

  Day 1

Secondary Outcomes (2)

• The time required for the pharmaceutical consultation

  Day 1

• satisfaction des patients

  Day 1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The patient is treated for multiple myeloma, is naive to any treatment and begins a chemotherapy protocol with oral therapy and whose course of care includes a stay in the Day Hospital or retrocessions.

You may qualify if:

• The patient must be a member or beneficiary of a health insurance plan
• The patient is at least 18 years old
• The patient is treated for multiple myeloma, is naive to any treatment and begins a chemotherapy protocol with oral therapy and whose course of care includes a stay in the Day Hospital or retrocessions.
• The subject is participating in another study
• The subject is under the protection of justice, guardianship or curatorship
• It is impossible to give informed information about
• The patient is pregnant, parturient, or breastfeeding
• The patient receives a follow-up by a home nurse for the administration of oral medication
• The patient is treated only with oral chemotherapy in the city
• The patient has early dementia.
• Translated with www.DeepL.com/Translator

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 23, 2019
• First Posted: August 5, 2019
• Study Start: June 1, 2015
• Primary Completion: December 31, 2016
• Study Completion: December 31, 2016
• Last Updated: August 5, 2019

Record last verified: 2019-07